Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial.

[1]  J. Andrews,et al.  Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study. , 2023, The lancet. Gastroenterology & hepatology.

[2]  J. Murray,et al.  Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity , 2021, The American journal of gastroenterology.

[3]  Tsung-Teh Wu,et al.  TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. , 2021, Gastroenterology.

[4]  Robert P. Anderson,et al.  Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease , 2020, BMC Medicine.

[5]  Suzanne K. Lewis,et al.  Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. , 2020, Gastroenterology.

[6]  B. Lebwohl,et al.  Epidemiology, Presentation, and Diagnosis of Celiac Disease. , 2020, Gastroenterology.

[7]  S. Crowe,et al.  Celiac Disease , 2020, Annals of Internal Medicine.

[8]  C. Bernstein,et al.  Most Patients With Celiac Disease on Gluten-free Diets Consume Measurable Amounts of Gluten. , 2019, Gastroenterology.

[9]  S. Acaster,et al.  Elevated serum interleukin‐2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease , 2019, Alimentary pharmacology & therapeutics.

[10]  J. Macdougall,et al.  Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease , 2019, Alimentary pharmacology & therapeutics.

[11]  J. Hubbell,et al.  Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes , 2019, Nature Biomedical Engineering.

[12]  P. H. Green,et al.  Global Prevalence of Celiac Disease: Systematic Review and Meta‐analysis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  R. Xavier,et al.  Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. , 2017, The lancet. Gastroenterology & hepatology.

[14]  L. Sollid,et al.  T Cells in Celiac Disease , 2017, The Journal of Immunology.

[15]  E. Wambre.  Effect of allergen-specific immunotherapy on CD4+ T cells , 2015, Current opinion in allergy and clinical immunology.

[16]  J. Murray,et al.  Practical insights into gluten-free diets , 2015, Nature Reviews Gastroenterology &Hepatology.

[17]  J. Murray,et al.  Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials , 2015, Gastroenterology report.

[18]  Mark M Davis,et al.  Dietary gluten triggers concomitant activation of CD4+ and CD8+ αβ T cells and γδ T cells in celiac disease , 2013, Proceedings of the National Academy of Sciences.

[19]  B. Jabri,et al.  Vaccine against autoimmune disease: antigen-specific immunotherapy. , 2013, Current opinion in immunology.

[20]  A. Rubio‐Tapia,et al.  ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease , 2013, The American Journal of Gastroenterology.

[21]  S. Acaster,et al.  Celiac Disease Symptom Frequency and Severity Using A Disease‐Specific Patient‐Reported Outcome Diary: Observations From A Psychometric Validation Study in 202 Patients: 1509 , 2012 .

[22]  S. Kupfer,et al.  Pathophysiology of celiac disease. , 2012, Gastrointestinal endoscopy clinics of North America.

[23]  F. Koning,et al.  Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules , 2012, Immunogenetics.

[24]  Percy A. Knolle,et al.  Antigen-presenting cell function in the tolerogenic liver environment , 2010, Nature Reviews Immunology.

[25]  C. Mulder,et al.  Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. , 2002, American journal of clinical pathology.

[26]  P. Howdle,et al.  Serum interleukin-2-receptor in coeliac disease: response to treatment and gluten challenge. , 1989, Clinical and experimental immunology.

[27]  E. S. Fox,et al.  Clearance of gut-derived endotoxins by the liver. Release and modification of 3H, 14C-lipopolysaccharide by isolated rat Kupffer cells. , 1989, Gastroenterology.

[28]  E. Thorsby,et al.  Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer , 1989, The Journal of experimental medicine.